Estrogens Maintain Bone Mass by Regulating Expression of Genes Controlling Function and Life Span in Mature Osteoclasts

Estrogens play a key role in regulation of bone mass and strength by controlling activity of bone‐forming osteoblasts and bone‐resorbing osteoclasts. Cellular effects of estrogens are mediated predominantly by the action of estrogen receptor alpha (ERα). In earlier studies, ablation of the ERα gene in mice did not result in osteoporotic phenotypes due to systemic endocrine disturbance and compensatory effects of elevated levels of testosterone. Despite the relatively well‐established effects in osteoblasts, little is known about the direct action of estrogen in osteoclasts. Development in the last decade of more sophisticated genetic manipulation approaches opened new possibilities to explore cell‐specific roles of nuclear receptors in bone tissue. Recently, we have generated osteoclast‐specific ERα gene knockout mice and shown that in vivo estrogens directly regulate the life span of mature osteoclasts by inducing the expression of pro‐apoptotic Fas ligand (FasL). Inhibitory effects of estrogens on osteoclast function were further studied in vitro. We observed sufficiently detectable ERα expression in osteoclasts differentiating from primary bone marrow cells or RAW264 cells, although levels of ERα were decreasing during progression of the differentiation into mature osteoclasts. Treatment with estrogens led to reduction in expression of osteoclast‐specific genes controlling bone resorption activity. However, estrogens did not affect the size of multinucleated osteoclasts or number of nuclei in a mature osteoclast. In conclusion, in osteoclasts, estrogens function to inhibit bone resorption activity and vitality rather than differentiation.

[1]  M. McKee,et al.  Endocrine Regulation of Energy Metabolism by the Skeleton , 2007, Cell.

[2]  K. Korach,et al.  Estrogen receptors and human disease. , 2006, The Journal of clinical investigation.

[3]  V. Vogel,et al.  Breast cancer risk management. , 2007, Clinical breast cancer.

[4]  S. Khosla,et al.  Mechanisms of sex steroid effects on bone. , 2005, Biochemical and biophysical research communications.

[5]  L. Fitzpatrick Estrogen therapy for postmenopausal osteoporosis. , 2006, Arquivos brasileiros de endocrinologia e metabologia.

[6]  Sheila J. Jones,et al.  Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[7]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[8]  J. Gustafsson,et al.  Elucidation of estrogen receptor function in bone with the use of mouse models , 2002, Trends in Endocrinology & Metabolism.

[9]  W. Reith,et al.  Conditional gene targeting in macrophages and granulocytes using LysMcre mice , 1999, Transgenic Research.

[10]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[11]  Mone Zaidi,et al.  Skeletal remodeling in health and disease , 2007, Nature Medicine.

[12]  P. Chambon,et al.  Skin abnormalities generated by temporally controlled RXRα mutations in mouse epidermis , 2000, Nature.

[13]  Ji-shuai Zhang,et al.  Transgenic mice that express Cre recombinasein hypertrophic chondrocytes , 2005, Genesis.

[14]  R. Baron,et al.  A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradiol receptor-deficient mice. , 2003, The Journal of clinical investigation.

[15]  Heidi D Nelson,et al.  Postmenopausal hormone replacement therapy: scientific review. , 2002, JAMA.

[16]  S. Boonen,et al.  Androgens and bone. , 2004, Calcified tissue international.

[17]  M. Kelz,et al.  Regulating ΔFosB expression in adult tet-off-ΔFosB transgenic mice alters bone formation and bone mass , 2002 .

[18]  G. Mundy Osteoporosis and inflammation. , 2007, Nutrition reviews.

[19]  Kozo Nakamura,et al.  Suppressive function of androgen receptor in bone resorption , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Chambon,et al.  Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. , 2007, Cell.

[21]  H. Takayanagi Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.

[22]  T. Chambers,et al.  Secretion of tartrate‐resistant acid phosphatase by osteoclasts correlates with resorptive behavior , 2006, Journal of cellular biochemistry.

[23]  S. Cummings,et al.  Recommendations for the Clinical Evaluation of Agents for Treatment of Osteoporosis: Consensus of an Expert Panel Representing the American Society for Bone and Mineral Research (ASBMR), the International Society for Clinical Densitometry (ISCD), and the National Osteoporosis Foundation (NOF) , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[24]  P. Chambon,et al.  Estrogen Prevents Bone Loss via Estrogen Receptor α and Induction of Fas Ligand in Osteoclasts , 2007, Cell.

[25]  八木 満 DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells , 2006 .

[26]  P. Chambon,et al.  Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. , 2000, Development.

[27]  M. Karsdal,et al.  Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts. , 2006, DNA and cell biology.

[28]  J. Vacher,et al.  Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice , 2005, Genesis.